期刊
LEUKEMIA RESEARCH
卷 71, 期 -, 页码 27-33出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2018.06.010
关键词
Acute myeloid leukemia; Cost; Healthcare utilization; Healthcare burden; Elderly
资金
- Millennium Pharmaceuticals, Inc., Cambridge, MA, USA of Takeda Pharmaceutical Company Limited
This retrospective claims database study examined healthcare utilization (HCU) and costs associated with acute myeloid leukemia (AML) in 237 elderly patients who received chemotherapy or a stem cell transplant (SCT) following AML diagnosis. Patients with secondary AML were excluded. Over the entire follow-up period, 92.0% of patients had >= 1 inpatient admission; 85.7% had >= 1 AML-related admission, and 42.6% had >= 1 non-AML-related admission. During inpatient admissions, 39.2% of patients had >= 1 intensive care unit (ICU) admission, with 20.7% having >= 1 AML-related ICU admission, and 27.8% having >= 1 non-AML-related ICU admission. Total mean per-patient per-month (PPPM) costs over the follow-up period were $25,243 (SD: $21,909), with costs from Year 1 ($27,756 [SD: $22,121]) more than double those in Year 2 ($12,953 [SD: $26,334]) following AML diagnosis. The majority of total costs were medical ($24,512 PPPM [SD: $21,704]), which included inpatient admissions ($6548 PPPM [SD: $10,777]), other outpatient visits ($5021 PPPM [SD: $7997]), supportive care ($3640 PPPM [SD: $5589], and chemotherapy administration ($2029 PPPM [SD: $2345]). Healthcare costs of treated elderly AML patients are substantial, particularly in the first year following diagnosis. Further research is needed to understand factors contributing to high costs in various settings of care for elderly AML patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据